Study Looks at Cardiotoxicity Associated with Sunitinib

Share this content:

SAN FRANCISCO—Researchers are concerned about cardiotoxicity associated with sunitinib, a treatment for advanced kidney cancer.

 

Of 48 assessable patients treated with the drug at Stanford University Comprehensive Cancer Center in Palo Alto, Calif., six (12.5%) experienced grade 3/4 left ventricular dysfunction during treatment, a rate much higher than reported previously, investigators said. All presented with symptoms of heart failure.

 

Findings were reported here at the 2008 Genitourinary Cancers Symposium.

 

You must be a registered member of Renal and Urology News to post a comment.